Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Simona Soverini, Luana Bavaro, Caterina De Benedittis, Margherita Martelli, Alessandra Iurlo, Nicola Orofino, Simona Sica, Federica Sorà, Francesca Lunghi, Fabio Ciceri, Sara Galimberti, Claudia Baratè, Massimiliano Bonifacio, Luigi Scaffidi, Fausto Castagnetti, Gabriele Gugliotta, Francesco Albano, Antonella Vita Russo Rossi, Fabio Stagno, Francesco di Raimondo, Mariella D’Adda, Eros di Bona, Elisabetta Abruzzese, Gianni Binotto, Rosaria Sancetta, Marzia Salvucci, Isabella Capodanno, Mariella Girasoli, Sabrina Coluzzi, Immacolata Attolico, Caterina Musolino, Elisabetta Calistri, Mario Annunziata, Monica Bocchia, Stefania Stella, Anna Serra, Santa Errichiello, Giuseppe Saglio, Fabrizio Pane, Paolo Vigneri, Flavio Mignone, Maria Antonella Laginestra, Stefano Aldo Pileri, Antonio Percesepe, Elena Tenti, Gianantonio Rosti, Michele Baccarani, Michele Cavo, Giovanni Martinelli

Blood (2020) 135 (8): 534–541.

https://doi.org/10.1182/blood.2019002969

Published: 2020

Includes: Supplemental data

Journal Articles

Comparative Monitoring of Minimal Residual Disease (MRD) By RT-Quantitative (RT-qPCR) and Digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) Patients Treated with TKIs for Recognition of Stable Deep Molecular Response (DMR) and Identification of Best Candidates to TKIs Treatment Discontinuation

Blood (2018) 132 (Supplement 1): 3012.

https://doi.org/10.1182/blood-2018-99-112391

Published: 2018

Journal Articles

What's Next in CML - a Prospective Study Evaluating Sanger Sequencing and Next Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain (KD) Mutation Screening

Simona Soverini, PhD, Luana Bavaro, Caterina De Benedittis, PhD, Margherita Martelli, Stefania Stella, PhD, Paolo Vigneri, MD PhD, Alessandra Iurlo, MD PhD, Nicola Orofino, MD, Simona Sica, MD, Federica Sorà, MD, Sara Galimberti, PhD MD, Claudia Baratè, MD PhD, Francesco Albano, MD, Antonella Russo Rossi, MD, Fabio Ciceri, MD, Francesca Lunghi, MD, Fausto Castagnetti, MD, Gabriele Gugliotta, MD PhD, Gianantonio Rosti, MD, Elena Tenti, PhD, Fabio Stagno, MD PhD, Elisabetta Novella, PhD, Eros Di Bona, MD, Massimiliano Bonifacio, MD, Elisabetta Abruzzese, MD PhD, Marzia Salvucci, MD, Mariella D'Adda, MD, Rosaria Sancetta, MD, Elisabetta Calistri, MD, Monica Bocchia, Isabella Capodanno, MD, Giuseppina Spinosa, MD, Maria Antonella Laginestra, PhD, Santa Errichiello, PhD, Anna Serra, Dr, Francesca Carnuccio, Dr, Sabrina Coluzzi, PhD, Mario Annunziata, MD, Caterina Musolino, MD, Fabrizio Pane, MD, Giuseppe Saglio, MD PhD, Michele Baccarani, MD, Michele Cavo, MD, Giovanni Martinelli, MD

Blood (2017) 130 (Supplement 1): 248.

https://doi.org/10.1182/blood.V130.Suppl_1.248.248

Published: 2017

Journal Articles

The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy

Simona Soverini, Caterina De Benedittis, Stefania Stella, Anna Serra, Francesca Carnuccio, Santa Errichiello, PhD, Luana Bavaro, Fausto Castagnetti, MD, Alessandra Iurlo, MD, Nicola Orofino, MD, Federica Sorà, Simona Sica, Sara Galimberti, MD PhD, Claudia Baratè, Federica Mottadelli, Margherita Martelli, Elisabetta Novella, Eros Di Bona, MD, Giorgina Specchia, Francesco Albano, Elisabetta Abruzzese, MD, Fabio Ciceri, MD, Francesca Lunghi, MD, Carmen Fava, MD, Giovanna Rege Cambrin, MD, Luigia Luciano, Massimo Breccia, MD, Clementina Caracciolo, MD, Marco Santoro, Francesco Di Raimondo, MD, Gabriele Gugliotta, Cristina Papayannidis, MD PhD, Giovanni Cazzaniga, Manuela Mancini, Rosaria Sancetta, Renato Bassan, Caterina Musolino, MD, Giuseppina Spinosa, Silvana Franca Capalbo, Mario Annunziata, MD, Michele Cavo, MD, Gianantonio Rosti, Michele Baccarani, Paolo Vigneri, Giuseppe Saglio, MD, Fabrizio Pane, Giovanni Martinelli

Blood (2016) 128 (22): 3097.

https://doi.org/10.1182/blood.V128.22.3097.3097

Published: 2016

Journal Articles

High BCR-ABL/GUS IS Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib

Blood (2015) 126 (23): 4049.

https://doi.org/10.1182/blood.V126.23.4049.4049

Published: 2015

Journal Articles

High BCR-ABL/GUS IS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib

Blood (2013) 122 (21): 1495.

https://doi.org/10.1182/blood.V122.21.1495.1495

Published: 2013

Journal Articles

High BCR-ABL Levels At Diagnosis Are Associated with Unfavorable Responses to Imatinib Mesylate.

Blood (2012) 120 (21): 2790.

https://doi.org/10.1182/blood.V120.21.2790.2790

Published: 2012

Journal Articles

BCR-ABL IS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy.

Paolo Vigneri, MD, PhD, Fabio Stagno, MD, Stefania Stella, PhD, Alessandra Cupri, MD, PhD, Michele Massimino, PhD, Agostino Antolino, MD, Vincenzo Abbadessa, MD, Maura Brugiatelli, MD, Patrizia Guglielmo, MD, Caterina Musolino, MD, Diamante Turri, MD, Mario Russo, MD, Guido Pagnucco, MD, Michele Rizzo, MD, Maurizio Musso, MD, Fortunato Morabito, MD, Luciano Levato, Angelo Messina, MD, Francesco Di Raimondo, MD

Blood (2010) 116 (21): 3426.

https://doi.org/10.1182/blood.V116.21.3426.3426

Published: 2010

Journal Articles

Treatment with TKIs Overcomes Imatinib Resistance through the PLCgamma-1 Signaling Pathway In Imatinib Resistant Human CML Cell Lines

Alessandra Romano, Paolo Vigneri, MD, PhD, Chiara Romano, Calogero Vetro, MD, Stefania Stella, PhD, Michele Massimino, PhD, Fabio Stagno, MD, Francesco Di Raimondo, Lance Liotta, Virginia Espina

Blood (2010) 116 (21): 4468.

https://doi.org/10.1182/blood.V116.21.4468.4468

Published: 2010

Journal Articles

Sustained Responses and Resistance to Imatinib Mesylate in the First 173 Chronic Myeloid Leukemia Patients Accrued by the SCREEN Multicenter Study: First Interim Report.

Blood (2009) 114 (22): 4276.

https://doi.org/10.1182/blood.V114.22.4276.4276

Published: 2009

Journal Articles

Lentiviral Engineered T Regulatory Cells Effectively Inhibit Lymphocytes Alloreactivity across Major HLA Barriers

Dario Sangiolo, MD, Noela Jordaney, Giulia Mesiano, Paola Circosta, Angela Elia, Stefania Stella, Maja Todorovic, Fabrizio Carnevale-Schianca, Massimo Aglietta, Alessandro Cignetti

Blood (2008) 112 (11): 3515.

https://doi.org/10.1182/blood.V112.11.3515.3515

Published: 2008

Journal Articles

Over 20% of Patients with Chronic Lymphocytic Leukemia Carry Stereotyped Receptors: Pathogenetic Implications and Clinical Correlations.

Blood (2006) 108 (11): 26.

https://doi.org/10.1182/blood.V108.11.26.26

Published: 2006

Journal Articles

Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations

Blood (2006) 109 (1): 259–270.

https://doi.org/10.1182/blood-2006-03-012948

Published: 2006

Includes: Supplemental data

Journal Articles

Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene

Paolo Ghia, Kostas Stamatopoulos, Chrysoula Belessi, Carol Moreno, Stefania Stella, Giuseppe Guida, Ariane Michel, Marta Crespo, Nikolaos Laoutaris, Emili Montserrat, Achilles Anagnostopoulos, Guillaume Dighiero, Athanasios Fassas, Federico Caligaris-Cappio, Frédéric Davi

Blood (2005) 105 (4): 1678–1685.

https://doi.org/10.1182/blood-2004-07-2606

Published: 2005

Journal Articles

Pathogenetic Implications from the Analysis of Immunoglobulin Genes in Chronic Lymphocytic Leukemia of Mediterranean Ancestry: The Lesson of the IGHV3-21 Gene.

Paolo Ghia, MD, PhD, Kostas Stamatopoulos, MD, Chrysoula Belessi, MD, Carol Moreno, MD, Stefania Stella, PhD, Giuseppe Guida, MD, Ariane Michel, PhD, Marta Crespo, PhD, Nikolaos Laoutaris, MD, Emili Montserrat, MD, Achilles Anagnostopoulos, MD, Guillaume Dighiero, MD, Athanasios Fassas, MD, Federico Caligaris-Cappio, MD, Frederic Davi, PhD

Blood (2004) 104 (11): 771.

https://doi.org/10.1182/blood.V104.11.771.771

Published: 2004

Journal Articles

Monoclonal CD5 + and CD5 - B-lymphocyte expansions are frequent in the peripheral blood of the elderly

Paolo Ghia, Giuseppina Prato, Cristina Scielzo, Stefania Stella, Massimo Geuna, Giuseppe Guida, Federico Caligaris-Cappio

Blood (2004) 103 (6): 2337–2342.

https://doi.org/10.1182/blood-2003-09-3277

Published: 2004

Journal Articles

CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5 + B lymphocytes

Luisa Granziero, Paola Circosta, Cristina Scielzo, Elisa Frisaldi, Stefania Stella, Massimo Geuna, Silvia Giordano, Paolo Ghia, Federico Caligaris-Cappio

Blood (2003) 101 (5): 1962–1969.

https://doi.org/10.1182/blood-2002-05-1339

Published: 2003

Journal Articles

The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression

Paolo Ghia, Giuseppe Guida, Stefania Stella, Daniela Gottardi, Massimo Geuna, Giuliana Strola, Cristina Scielzo, Federico Caligaris-Cappio

Blood (2003) 101 (4): 1262–1269.

https://doi.org/10.1182/blood-2002-06-1801

Published: 2003

NARROW

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

What's Next in CML - a Prospective Study Evaluating Sanger Sequencing and Next Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain (KD) Mutation Screening

The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy

High BCR-ABL/GUS IS Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib

High BCR-ABL/GUS IS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib

High BCR-ABL Levels At Diagnosis Are Associated with Unfavorable Responses to Imatinib Mesylate.

BCR-ABL IS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy.

Treatment with TKIs Overcomes Imatinib Resistance through the PLCgamma-1 Signaling Pathway In Imatinib Resistant Human CML Cell Lines

Sustained Responses and Resistance to Imatinib Mesylate in the First 173 Chronic Myeloid Leukemia Patients Accrued by the SCREEN Multicenter Study: First Interim Report.

Lentiviral Engineered T Regulatory Cells Effectively Inhibit Lymphocytes Alloreactivity across Major HLA Barriers

Over 20% of Patients with Chronic Lymphocytic Leukemia Carry Stereotyped Receptors: Pathogenetic Implications and Clinical Correlations.

Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations

Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene

Pathogenetic Implications from the Analysis of Immunoglobulin Genes in Chronic Lymphocytic Leukemia of Mediterranean Ancestry: The Lesson of the IGHV3-21 Gene.

Monoclonal CD5 + and CD5 - B-lymphocyte expansions are frequent in the peripheral blood of the elderly

CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5 + B lymphocytes

The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only